Morgan Stanley
NMRA icon

Morgan Stanley’s Neumora Therapeutics NMRA Stock Holding History

Morgan Stanley’s Portfolio NMRA Stock Details NMRA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$543K Sell
319,421
-184,398
-37% -$351K ﹤0.01% 5509
2026
Q1 		$982K Buy
503,819
+265,335
+111% +$688K ﹤0.01% 5150
2025
Q4 		$427K Sell
238,484
-36,283
-13% -$79.4K ﹤0.01% 5586
2025
Q3 		$500K Buy
274,767
+46,129
+20% +$74.6K ﹤0.01% 5499
2025
Q2 		$168K Sell
228,638
-623,734
-73% -$473K ﹤0.01% 5919
2025
Q1 		$852K Buy
852,372
+120,960
+17% +$207K ﹤0.01% 5080
2024
Q4 		$7.75M Buy
731,412
+377,721
+107% +$4.53M ﹤0.01% 3619
2024
Q3 		$4.67M Buy
353,691
+196,953
+126% +$2.3M ﹤0.01% 4011
2024
Q2 		$1.54M Buy
156,738
+91,363
+140% +$945K ﹤0.01% 4719
2024
Q1 		$899K Buy
65,375
+34,296
+110% +$554K ﹤0.01% 5016
2023
Q4 		$530K Buy
31,079
+30,679
+7,670% +$377K ﹤0.01% 5263
2023
Q3 		$5.64K Buy
+400
New +$5K ﹤0.01% 6885

Other funds holding NMRA

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $3.47B AUM 23.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Morgan Stanley's NMRA Position: Q2 2026 in Review

Morgan Stanley reduced its Neumora Therapeutics (NMRA) stake by 37% in Q2 2026, selling an estimated $351K and leaving 319,421 shares worth $543K. The position accounts for ﹤0.01% of the portfolio, ranked #5509.

Morgan Stanley first reported a position in NMRA in Q3 2023 and has held it in 12 quarters since. The position peaked at $7.75M in Q4 2024. 113 funds tracked by Wall St. Rank hold NMRA as of Q2 2026.

  • Morgan Stanley held 319,421 shares of Neumora Therapeutics worth $543K as of Q2 2026.
  • Morgan Stanley sold 184,398 Neumora Therapeutics shares in Q2 2026, an estimated $351K.
  • Neumora Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q2 2026, its #5509 holding.
  • Morgan Stanley first reported a position in Neumora Therapeutics in Q3 2023 and has held it in 12 quarters since.
  • Morgan Stanley's Neumora Therapeutics position peaked at $7.75M in Q4 2024.
  • 113 funds tracked by Wall St. Rank held Neumora Therapeutics as of Q2 2026.

Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.